Recent Updates
Recently added Catalysts
INSM

Insmed to Present at Two March Conferences Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Key Takeaway: BRIDGEWATER, N.J. , Feb. 24, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual inve

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
3.7%
average across 4 past catalysts
Cash runway
~39 mo
Minimal dilution risk
Lead asset
Brensocatib
Phase 3 · Non-Cystic Fibrosis Bronchiectasis

Full Press Release Details

BRIDGEWATER, N.J. , Feb. 24, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor events:
Each fireside chat will be webcast and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com . Each webcast will be archived for a period of 30 days following the conclusion of each live event.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States and the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey , with a growing footprint across Europe and in Japan . For more information, visit www.insmed.com .
Last updated: Feb 24, 2021